US 12,076,316 B2
Levorphanol prodrugs and processes for making and using them
Travis Mickle, Celebration, FL (US); Sven Guenther, Coralville, IA (US); and Sanjib Bera, Blacksburg, VA (US)
Assigned to ZEVRA THERAPEUTICS INC.
Filed by ZEVRA THERAPEUTICS, INC., Celebration, FL (US)
Filed on Dec. 14, 2021, as Appl. No. 17/550,328.
Application 17/550,328 is a continuation of application No. 16/604,710, granted, now 11,234,975, previously published as PCT/US2018/027263, filed on Apr. 12, 2018.
Claims priority of provisional application 62/485,890, filed on Apr. 14, 2017.
Claims priority of provisional application 62/485,891, filed on Apr. 14, 2017.
Prior Publication US 2022/0096463 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 221/28 (2006.01); A61K 31/439 (2006.01); A61K 31/485 (2006.01); A61K 47/54 (2017.01); A61K 45/06 (2006.01)
CPC A61K 31/485 (2013.01) [A61K 47/542 (2017.08); A61K 45/06 (2013.01)] 15 Claims
 
1. A compound of Formula 1:

OG Complex Work Unit Chemistry
where L1 and L2 are independently absent, or

OG Complex Work Unit Chemistry
Y1 and Y2 are independently either absent, or [A-X—Z]n where A, X, Z are independently selected for Y1 and Y2 and where A and Z are independent of each other, either absent or selected from the group of —O—, —S—, or —(CR1R2)k—,
where X is —(CR1R2)k—,
J is [M-W]p
where M is —(CR3R4)q—; and W is absent, or —O— or —S—
R1, and R2, are each independently selected for Y1 and Y2, and are, independent of each other, selected from H, alkyl, aryl, alkyl aryl, alkoxy, haloalkyl, or haloaryl
R3 and R4 are each independently selected from H, alkyl, aryl, alkyl aryl, alkoxy, haloalkyl, or haloaryl
for each Y1 and Y2, n is independently an integer of 1-4
for each repeating unit of [A-X—Z]n, when (CR1R2) is present, k is independently an integer of 1-4
p and q are independently selected from 1-4
Gm is absent, or selected independently of each other and, when present, each repeating subunit is independently selected from H, oxoacid, polyethylene glycol having from 2 to 5 ethylene oxide units, or a vitamin compound;
Gm2 is selected from oxoacid, polyethylene glycol having from 2 to 5 ethylene oxide units, or a vitamin compound;
where m is selected independently for G1 and G2, and is an integer of 1-4, except that m is 1 when G1 is a hydrogen atom;
or a pharmaceutically acceptable salt thereof.